Given the comparable in vitro performance of WSD-0922 to erlotinib, we next sought to assess the in vivo efficacy of these two EGFR TKIs using GBM12, GBM39, and GBM6 PDX orthotopic and flank tumor models. This evidence concerns the gene EGFR and neoplasm.